Literature DB >> 6292317

Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal human fibroblasts.

S H Gianturco, F B Brown, A M Gotto, W A Bradley.   

Abstract

Our previous studies showed that very low density lipoproteins, Sf 60-400 (VLDL), from hypertriglyceridemia subjects, but not VLDL from normolipemic subjects, suppress HMG-CoA reductase activity in normal human fibroblasts. To determine if this functional abnormality of hypertriglyceridemic VLDL resulted from differences in uptake of the VLDL by the low density lipoprotein (LDL) receptor pathway, we isolated VLDL subclasses from the d less than 1.006 g/ml fraction of normal and hypertriglyceridemic plasma by flotation through a discontinuous salt gradient for direct and competitive binding studies in cultured human fibroblasts. VLDL from the plasma of subjects with hypertriglyceridemia types 4 and 5 were at least as effective as normal LDL in competing for 125I-labeled LDL binding, uptake, and degradation when compared either on the basis of protein content or on a particle basis. By contrast, normolipemic Sf 60-400 VLDL were ineffective in competing with the degradation of 125I-labeled LDL, and Sf 20-60 VLDL (VLDL3) were less effective in reducing specific 125I-labeled LDL degradation than were LDL, consistent with their effects on HMG-CoA reductase activity. In direct binding studies, radiolabeled VLDL from hypertriglyceridemic but not normolipemic subjects were bound, internalized, and degraded with high affinity and specificity by normal fibroblasts. Uptake and degradation of iodinated hypertriglyceridemic VLDL Sf 100-400 showed a saturable dependence on VLDL concentration. Specific degradation plateaued at approximately 25 micrograms VLDL protein/ml, with a half maximal value at 6 micrograms/ml. The most effective competitor of hypertriglyceridemic VLDL uptake and degradation was hypertriglyceridemic VLDL itself. LDL were effective only at high concentrations. Uptake of normal VLDL by normal cells was a linear rather than saturable function of VLDL concentration. By contrast, cellular uptake of the smaller normal VLDL3 was greater than uptake of larger VLDL and showed saturation dependence. After incubation of normal VLDL with 125I-labeled apoprotein E, reisolated 125I-E-VLDL were as effective as LDL in suppression of HMG-CoA reductase activity, suggesting that apoE is involved in receptor-mediated uptake of large suppressive VLDL. We conclude that 1) hypertriglyceridemic VLDL Sf 60-400 are bound, internalized, and degraded by normal fibroblasts primarily by the high affinity LDL receptor-mediated pathway; 2) by contrast, normal VLDL, Sf 60-400 are bound, internalized, and degraded by normal fibroblasts primarily by nonspecific, nonsaturable routes; and 3) of the normal VLDL subclasses, only the smallest Sf 20-60 fraction is bound and internalized via the LDL pathway.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292317

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  14 in total

Review 1.  Fatty acid composition of the diet: impact on serum lipids and atherosclerosis.

Authors:  N Zöllner; F Tatò
Journal:  Clin Investig       Date:  1992-11

2.  In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Decreased enzyme catalytic efficiency in familial hypercholesterolemia.

Authors:  P W Stacpoole; D M Bridge; I M Alvarez; R B Goldberg; H J Harwood
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

3.  Modulation of lipid profile by fish oil and garlic combination.

Authors:  N C Morcos
Journal:  J Natl Med Assoc       Date:  1997-10       Impact factor: 1.798

Review 4.  Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic.

Authors:  M S Brown; J L Goldstein
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

5.  Roles of apolipoproteins B and E in the cellular binding of very low density lipoproteins.

Authors:  E S Krul; M J Tikkanen; T G Cole; J M Davie; G Schonfeld
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

6.  Relationship of an abnormal plasma lipoprotein to protection from atherosclerosis in the cholesterol-fed diabetic rabbit.

Authors:  P Brecher; A V Chobanian; D M Small; W Van Sickle; A Tercyak; A Lazzari; J Baler
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

7.  Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein epsilon 4 allele.

Authors:  N Bergeron; R J Havel
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

8.  Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides.

Authors:  Stuart B Prenner; Claire K Mulvey; Jane F Ferguson; Michael R Rickels; Anish B Bhatt; Muredach P Reilly
Journal:  Atherosclerosis       Date:  2014-07-22       Impact factor: 5.162

9.  Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective low density lipoprotein receptors.

Authors:  H H Hobbs; E Leitersdorf; C C Leffert; D R Cryer; M S Brown; J L Goldstein
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

10.  Circulating human C-reactive protein binds very low density lipoproteins.

Authors:  I F Rowe; A K Soutar; I M Trayner; G R Thompson; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.